Scholars Central

Conference abstractPublished 7 Mar 2019

Treat locally equals treat systemically: Targeting the tumor microenvironment clinically

Authors: Alejandro Camacho Hernandez

Sonora Cancer Research Center (CICS), USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There are many animal models treating the tumor microenvironment. However, there are very few in human studies. For such reason we design using different tumor cell lines and human peripheral blood mononuclear cells (PBMC´s). Afterwards we designed a clinical pilot trial approved by the local ethic committee. We used combinations of local therapy with repurposing drugs. We performed a systematic review of several potential drugs (N=12). For those drugs we decided according with the proof of principle studies use clinically in refractory cancer patients from different tumors the following drugs. Bortezomib, meloxicam, zoledronic acid, gemcitabine and naproxen. The treatment starts over on the inguinal and axillar lymph nodes areas at immunogenic doses. This approach was designed to modulate CD8, Ï?δ T cells and Th1. Refractory patients with diverse neoplasiaâ??s and Karnofsky > at 80% n=18 were treated with this combination. We started treating first IV and after one week we treated with subcutaneous (SC) injections in the primary tumor site and metastasis areas (2 ml per injection in each site). We selected the SC injection sites in base at the most recent CT scan. Several immunological assays such as peptide ELISA and cytokines IL-6, IL-12, TNF-alpha and IL-10 were measured. The treatment was well tolerated with minor adverse events such as nausea, flu-like symptoms, mild pain in the SC injections and diarrhea. The combination was able to reduce primary tumor, hepatic and lung metastasis in 11/18 patients. Additionally, IL-6 was downregulated in the 11 patients with response (p=0.01) and IL-12 was increased (p=0.005). When the stroma and tumoral microenvironment are treated locally there is genomic, stroma, innate and adaptive immune cells usually associated with immunosuppression. With this approach the tumor cells died mainly by necrosis and several molecules clinically relevant for instance DAMPS, calreticulin and heat shock proteins are able to impact the stop of tumor growth and metastasis. Importantly this combination was able to decrease myeloid derived suppressor cells. This protocol was able to activate the phagocytosis and maturation of dendritic cells after treatment. Treat locally treat systemically is very effective in comparision with systemic myeloablative chemotherapy, because we can develop very important modification of tumoral microenvironment, immunological system reactivation, and we can avoid myeloid suppressor cells, T-regs, neoangiogenesis, with less toxicity.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Alejandro Camacho Hernandez”